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Introduction
The limited case cluster of atypical pneumonia detected in central
China in December 2019, now known as Coronavirus Disease 2019
(Covid-19), converted into a million confirmed cases worldwide in
only 10 weeks. Declared a pandemic by the World Health Organization
(WHO) on 11 March 2020 (WHO, 2020) and passing the 3 million
mark on 27 April, the world is under formidable strain with respect to
public health, economy and personal life. Time and again we are alerted
about unforeseen, new effects of this disease, which brings to mind the
terms “known unknowns” and “unknown unknowns” used by former
U.S. Secretary of Defense Donald Rumsfield when referring to the lack
of evidence of weapons of mass destruction in Iraq ahead of the second
Gulf war, a fitting vocabulary as we again are faced with mass destruc-
tion, though this time of a different kind.
Critical questions
Rumsfield’s statement conceptualizes the distinction between the
questions we are aware of and those not even considered. Most of them
are fortuitously known unknowns, e.g., what is the origin of this virus?
How much longer will this pandemic go on? why do men develop seri-
ous symptoms more often than women? Are childhood infections with
other coronaviruses preventing infections in young people? Can non-
infected people be sheltered by those who have recovered (herd immu-
nity)? And perhaps the most important one, can lives be saved without
killing the economy?  There are also many unknown unknowns, such as
the recent understanding that the lungs are not the only target organ (El
Boussadani et al., 2020; Magro et al., 2020; Matías-Guiu et al., 2020;
Yao et al., 2020). This raises the question of whether Covid-19 is a sys-
temic disease, something supported by reports of cardiac involvement,
embolism and hypotension, which has changed about 5% of all cases
into life-threatening emergencies (Wadman et al., 2020). Indeed, the
virus acts very differently from influenza and can even lead to stroke in
young patients (Oxley et al., 2020). On the other hand, a large proportion
of patients show only mild symptoms. While the pathological reactions
could be explained by a high viral load, such as that sustained by some
doctors and nurses, that might release what has been called a ‘cytokine
storm’ in spite of (or perhaps rather because of) a strong immunity, a
minor viral challenge could allow sufficient time for the immune system
to mask the infection because of the longer incubation time of Covid-19
compared to influenza and the common childhood infections. This sup-
position could also explain the dual wave pathology expressed by clini-
cians with regard to patients who are initially hospitalized with modest
symptoms, then improve only to experience widespread pathology later
on. Overall, these observations and conjectures illustrate that we remain
in the dark regarding how Covid-19 operates.
At what stage of the pandemic are we?
The totality of active and recovered cases as shown in Figure 1
indicates that the increase of active cases is starting to slow down, while
the number of people who have recovered is rising faster than before.
Although this mainly applies to hospitalized and tested patients, it sug-
gests that the red curve will eventually go down and in doing so pre-
dominantly move individuals into the blue curve. Thus, there will be a
meeting point of the two curves, but when this will occur is too early to
say. Even if we accept the view of the Centre for Evidence-Based
Medicine (CEBM) at the University of Oxford, UK (CEBM, 2020) that
a large proportion of infections are silent, a rough estimate indicates that
less than 30 million people have so far been infected - a sobering
thought against the background that the Spanish flu reached 55% of the
world’s population, (Taubenberger & Morens, 2019).
As reported by China’s National Health Commission, the
country reached a peak of Covid-19 cases on 12 February 2020
followed by elimination of local dissemination by 19 March.
South Korea was not far behind with no new domestic cases
reported since 29 February. Indeed, all Southeast Asian countries
as well as Japan, New Zealand and Australia have reported only
modest numbers of confirmed cases and comparatively few
deaths, something seen also in South Africa where the low median
age (27 years) has been used as an explanation. In Europe, the sit-
uation is quite different with high death counts and continued new
Covid-19 infections in nearly all countries. The low number of
deaths in Germany is, however, surprising as this country has one
of the highest median ages in the world (47 years). Overall, how-
ever, even the European countries have reached the beginning of
a plateau with respect to new cases (https://www.worldometers.
info/ coronavirus/) and many are planning to begin opening up
after the lockdown that clearly flattened (and prolonged) the curve
relieving pressure on hospitals and intensive care. 
Why is there such a difference with respect to Covid-19
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between Europe and the U.S. on the one hand, and the Far East on
the other - is it just a question of management? Since a large num-
ber of pandemics originated in Asia, innate immunity against coro-
naviruses might be more common there than in the rest of the
world. Are we witnessing a replay of the the last 500 years of the
seafaring explorers who brought smallpox to the Americas
(Henderson et al., 1999) and took syphilis back to Europe (Harper
et al., 2008)?  Antibody studies will contribute to elucidating this
conjecture. 
The lack of clear metrics makes it difficult to estimate the true
fatality risk of Covid-19. The daily published figures refer to the
Case Fatality Rate (CFR), which is based on confirmed cases in
hospitals and mainly does not include people cared for in their own
homes or in care homes. Antibody tests will eventually enlarge the
base by adding those with silent infections, thereby moving closer
to what is called the Infection Fatality Rate (IFR), a measure that
is, by definition, lower than the CFR. Interestingly, the latter seems
to very recently have reached a plateau (perhaps even a peak) at
7%, which not only signals a break in the deadly attacks of the dis-
ease but also establishes a ceiling for the risk. The IFR will proba-
bly turn out to be not much higher than that for common influenza
even considering the 5% with extraordinary symptoms and the
fatalities in the old-age group. However, the high mortality in peo-
ple with chronic medical problems and the elderly, the latter possi-
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Table 1. A 100+ years of viral threats by influenza and coronaviruses.
Time and                     Viral species     Reproductive      World          People           Number of           Case                Reference         Impacta
name of                         (subtype)           ratio (R0)     population    infected           deaths           fatality
infection wave                                                                   (billion)      (million)         (million)        rate (%)
1889-1990 Russian flub           Influenza A                       2.1                        1.5                  300-900                         1                       0.1-0.3              Valleron et al., 2010            5
                                                 (H3N8/H2N2)                       
1918-1920 Spanish flub           Influenza A                       1.8                        1.8                500-1,000                  50-100                     2-3                   Taubenberger &              9
                                                       (H1N1)                                                                                                                                                                        Morens, 2006, 2019
1957-1958 Asian flub                Influenza A                       1.7                        2.9                      500                           1-4                       <0.2                    Hilleman, 2002                4
                                                       (H2N2)
1968-1969 Hong Kongb           Influenza A                       1.8                        3.5                      500                           1-4                       <0.2                    Hilleman, 2002                4
                                                       (H3N2)                             
2002-2004 SARSc                       SARS-CoV                        2.8                        6.4                8,098x10-6                 774x10-6                     9.6                          CDC, 2005                     1
2009-2010 Swine flub              Influenza A                       1.5                        6.9                  100-200               18,500 x 10-6                0.03                       WHO, 2011;                   2
                                                    (H1N1/09)                                                                                                       284,500 x 10-6                                      Dawood et al., 2012
2012-cont.  MERSc,d                 MERS-CoV                       <1                        7.8                2,519x10-6                866 x 10-6                   34.4                       WHO, 2020a                   1
2020-2021? Covid-19b              SARS-CoV-2                      2.6e                       7.8                      3.6f                           0.2f                         7.0f                     Worldometerg               10?
aon a scale of 0-10; bPandemic; cEpidemic; dStill ongoing epidemic but with few new cases; ehttps://www.cebm.net/covid-19/when-will-it-be-over-an-introduction-to-viral-reproduction-numbers-r0-and-re/; fas of 6 May
2020; ghttps://www.worldometers.info/coronavirus/. 
Figure 1. When will these curves cross?
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bly due to immunosenescence as suggested by Lambert et al. in
influenza (2012), makes one wonder if it will ever be possible to
extract confounding factors and produce an unequivocal fatality
rate for the general public. 
Previous pandemics
Historically, viruses have emerged time and again only to dis-
appear when immunity developed in the affected population.
Indeed, epidemics, let alone pandemics, may not have been a prob-
lem until humans first gathered in cities about 5000 years ago as
viruses require continuous access to immunologically naive peo-
ple. If so, a brief video of the growth of habitation from 3,700 B.C.
until modern days (http://metrocosm.com/history-of-cities/) not
only shows the origin of cities, but also visualizes the growing
prospects for viral outbreaks. The reflection that humankind has
grown by 410% over the last 100 years (https://ourworldinda-
ta.org/world-population-growth) is disturbing as this has also
increased human encroachment into habitats previously belonging
to other species. This has brought humans in closer contact with
wildlife potentially harbouring new and unknown viruses, increas-
ing the risk of animal virus’s jumping species boundaries to infect
humans This fact alone, ensures that Covid-19 is likely to be fol-
lowed by future zoonotic events and other pandemics in the not too
distant future. 
The major pandemics of the last century all emerged, in one
way or another, from animal viruses that have adapted to humans.
However, as seen in Table 1, mortality rates have held well below
1% lately (WHO, 2011) with, counterintuitively, the Swine flu
turning out to have had an unusually low case fatality rate (CFR)
even though it infected more people than any previously known
pandemic in spite of a comparatively low reproductive ratio
(R0=1.7). How does Covid-19 fit into this list? 
In contrast to the Spanish and Asian flu pandemics that mainly
hit those below 30 years of age with older people probably protect-
ed by remaining immunity from infections in their youth, older
people suffer the greatest risk this time around. For Covid-19, the
high R0 (2.6) stands out as does the CFR, which has led to a polit-
ical response affecting mobility tough enough to slow down the
general economy so strongly that the overall impact of this pan-
demic is overtaking that of the Spanish flu. 
Case tracing
One of the papers on Covid-19 published in this issue of
Geospatial Health regards the large population exchange between
Wuhan - the epicentre of this disease, the Yangtze River Delta area
and Zhejiang Province concluding that identification of the spa-
tiotemporal trends of this kind should be the first step when devel-
oping effective policies to manage epidemics (Ye and Hu, 2020).
This exchange can be followed in detail by electronic surveillance
as discussed in the preceding editorial. A way to do so with mini-
mal managerial effort and time loss would be to analyze geolocat-
ed Twitter traffic as suggested by Bisanzio et al. (2020). These
authors show that data generated by social media can be used to
predict the spatiotemporal spread of infectious diseases based on a
study cohort of Twitter users. They studied human mobility pat-
terns with reference to Covid-19, paying special attention to air-
ports with scheduled flights from Wuhan using a validated
Infectious Disease Vulnerability Index (IDVI) to identify the
capacity to prepare for and respond to infectious disease threats in
countries receiving travellers from this city.
Digital solutions for case tracing are now being developed and
tested in many countries, where citizens are engaged to assist the
health authorities’ epidemiological surveillance of the spread of
Covid-19 infection in their country. The applications speed up con-
tact with people exposed and can help support decisions concern-
ing a safe and data-based, gradual opening of society. Examples
include the development of national smartphone app-based
approaches to trace the virus, such as the ‘C-19 Covid Symptom
Tracker’ (https://covid.joinzoe.com/) in use in UK since March




Norway and ‘Covidsafe’ in Australia (https://www.health.gov.au/
resources/apps-and-tools/covidsafe-app) in April. These apps let
citizens voluntarily self-report symptoms and other health-related
data. A similar system will soon be available in Italy under the
name ‘Immuni’, while Germany has chosen to support an approach
available from Google and Apple based on a decentralized soft-
ware architecture with the data stored in the users’ own phones.
The question of immunity
An early, significant step forward was the sequencing and shar-
ing of the SARS-CoV-2 genome in a sample from a Chinese
patient on 5 January 2020 (Zhang and Holmes, 2020). The virus
causing Covid-19 turned out to be a single, positive-stranded RNA
with close to 30,000 nucleotides, which was later confirmed by
sequenced samples from other countries. This early success helped
develop the first diagnostic assays and has been crucial for the
ongoing vaccine development. Interestingly, specific IgG and IgM
antibodies were followed in a limited number of Covid-19 patients
and revealed seroconversion after 11 and 14 days, respectively,
with IgG reaching its highest concentration four weeks after the
onset of symptoms (Oxley et al., 2020). Detection of specific anti-
bodies against SARS-CoV-2 indicates previous infection by this
virus, but to be epidemiologically useful testing must be based on
sufficiently large samples. This approach is now coming to the fore
after delays due to problems with assay production and distribu-
tion. The very first test results of s indicate that the virus had come
the U.S. prior to the previously notified first cases in Washington
State as positive results were recovered from two persons in Santa
Clara, California who died in early and mid-February 2020
(https://www.nytimes.com/2020/04/22/us/coronavirus-first-unit-
ed-states-death.html). It is also plausible that the virus has been cir-
culating in China long before the first reported case, a 55-year-old
individual from Hubei Province in China diagnosed in mid-
November 2019 (Ma, 2020). 
The importance of immunity might soon be recognized in the
U.S. as some States have begun opening up, prematurely according
to the experts, while others remain in lockdown. Extended anti-
body detection in randomly selected samples of people in New
York and Stockholm has already been carried out. According to
News-casts (https://www.nytimes.com/2020/04/23/nyregion/coro-
navirus-antibodies-test-ny.html) 20% positivity, presumably corre-
sponding to a similar level of immunity, has been found. This is
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promising though too low to be useful as herd immunity (at least
>60% needed). Future testing will hopefully show higher levels,
which is important as the SARS-CoV-2 virus will never disappear
completely and may return at any time depending on the general
status of immunity, the longevity of which will remain unknown
for a long time. 
That transmission of the disease seems to have stopped in
China as well as in some other countries in the region, and the fact
that the lockdown in Wuhan was lifted without undue results is
good news. The slower climb of mortality in Europe together with
indications that the rate of new cases generally does not increase
further is supporting evidence, but only large-scale testing for spe-
cific antibodies can provide a clear answer regarding the role of
immunity. Individual quarantine should not be lifted before
research has conclusively shown that the presence of specific anti-
bodies corresponds to immunity. So far, the strongest confirmation
of the development of immunity comes from a preprint of a paper
based on experiments with a few Rhesus macaque monkeys (Bao
et al., 2020) and the news release of successful, extended testing of
a prototype vaccine in the same species of animal at the Jenner
Institute at Oxford University, UK (http://www.cubasi.cu/en/news/
covid-19-oxford-university-vaccine-proves-effective-monkeys).
Vaccine(s) or drug(s)
There are basically two ways of stopping an infectious disease,
be it a due to a virus, a bacterium or a parasite. An effective drug
provides immediate relief, while a vaccine can prevent reinfection
in the long term.
With respect to drug development, nucleotide inhibitors have
been shown to be active against RNA viruses (Elfiky, 2020).
Incidentally, hydroxychloroquine is one of these but its usefulness
has not been borne out and the U.S. Food and Drug Administration
(FDA) cautions against its use with Covid-19 outside hospital set-
tings due to the risk of heart rhythm problems. There are several
other compounds that also interfere with viral reproduction by
binding to the viral RNA-dependent RNA polymerase (the enzyme
that catalyzes RNA replication). One of them, RemdesivirTM, is
currently in Phase 3 clinical studies (testing large numbers of peo-
ple in the field) to evaluate the safety and efficacy in adults diag-
nosed with Covid-19. Initial results are said to be positive, but have
yet to be published. 
Regarding vaccines, there are now more than 100 candidates
(Thanh et al., 2020), but only a few have reached an advanced
stage and only three are in clinical trials for safety (Phase I).
However, even if efficacy can be demonstrated, scaled-up produc-
tion will become a bottleneck given the high number of doses
needed to keep the world safe. Therefore, even if it is plausible that
an efficacious prototype vaccine could be ready before the end of
this year, experience based on distribution of other vaccines indi-
cates that a tentative date for commercial release of large numbers
of doses would still be another year away, with the possibility of
vaccination perhaps becoming available earlier for risk groups.
Nevertheless, access to the virus genome has reduced the laborato-
ry work from decades to months and further savings will be
achieved as many of the steps normally required before a vaccine
is released for public use will probably be cut short once safety has
been shown. Vaccine evaluation can therefore be expected to move
almost directly from Phase I to Phase IV (continued studies after
the commercial release of a product). 
The main editorial for this May issue of Geospatial Health was
published the last day of April 2020, unusually early affected by
the advent of Covid-19. It is now followed by this addendum,
again unprecedented and due to the speed of new developments
and publications related to this new disease.
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